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1. Introduction 
Autism Spectrum Disorders (ASD) are associated with atypical social, behavioral and 
physiological characteristics. Here we outline an emerging connection among the increased 
incidence of epilepsy, disrupted sleep and perseverative behaviors exhibited and sought by 
persons with autism. Specifically, we propose that persons with autism can benefit from 
increased levels of adenosine, a powerful inhibitory neuromodulator and the core molecule 
of adenosine triphosphate (ATP). We review the literature and present recent data obtained 
via a customized questionnaire administered to parents of children with a confirmed autism 
diagnosis. This customized questionnaire demonstrates that symptoms of autism are 
reduced subsequent to stimuli predicted to increase adenosine. In addition, we present 
evidence from the literature and pilot data from a retrospective study of children with 
epilepsy or epilepsy and autistic behavior who were treated with a ketogenic diet, a long-
established anticonvulsant therapy that recently has been shown to suppress seizures via 
the adenosine A1 receptor (A1R) subtype. Our discussion focuses on the actions of adenosine 
in the central nervous system, with multiple implications for ASD, and the potential for 
developing new evidence-based therapies. Taken together, published peer-reviewed 
research and recent preliminary research suggest that adenosine could help resolve multiple 
physiological and behavioral symptoms of ASD.   
2. Adenosine - role in physiology and behavior 
Adenosine is a purine molecule present throughout the body. In the central nervous system 
it is increasingly appreciated as a homeostatic bioenergetic network regulator (Boison et al., 
2011). Fundamental to its homeostatic influences on neuronal networks are adenosine’s 
integral roles in metabolism and cell signaling, and its regulatory influence as an obligate 
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by-product of transmethylation reactions. In terms of metabolism, adenosine is the core of 
arguably the most important purine, adenosine triphosphate (ATP), the pre-eminent cell 
energy molecule, and also of related adenine nucleotides adenosine diphosphate (ADP) and 
adenosine monophosphate (AMP); these purines determine overall cell energy charge 
(Dunwiddie & Masino, 2001). In terms of signaling, adenosine binds to a family of 
membrane-bound G protein-coupled cell-surface receptors (A1, A2A, A2B, A3) to influence 
membrane potential, synaptic transmission and second messenger signaling (Ralevic & 
Burnstock, 1998; Dunwiddie & Masino, 2001). Its ubiquitous presence in every cell, 
widespread receptor distribution, and tonic levels throughout the extracellular space - 
sufficient to activate a subset of these receptors - make adenosine a key player in neuron-glia 
interactions (Fields & Burnstock, 2006), and able to exert a dynamic and broad regulatory 
influence.  
Adenosine A1 receptors (A1Rs) and adenosine A2A receptors (A2ARs) have the highest 
affinity for adenosine and the most predominant ongoing functional effects in the central 
nervous system (Fredholm et al., 2005). Generally, A1Rs serve to decrease synaptic 
transmission and decrease cAMP, whereas A2ARs facilitate transmission and increase cAMP 
(Schulte & Fredholm, 2003). A1Rs are expressed widely throughout the brain (Goodman et 
al., 1982), and A2ARs are highly concentrated in the basal ganglia and olfactory tubercle 
(Rosin et al., 2003). Thus, many effects of adenosine are location- and subtype-specific. These 
two receptor subtypes are both targeted by caffeine, a non-selective A1R/A2R antagonist and 
the most widely used psychoactive drug world-wide (Fredholm et al., 1999).  
A1Rs exert a tonic inhibition on excitatory transmission via pre- and postsynaptic actions 
(Ralevic & Burnstock, 1998; Dunwiddie & Masino, 2001). The inhibitory effects of A1Rs are 
well-known to prevent and stop seizures (Dunwiddie & Worth, 1982), reduce anxiety (Florio 
et al., 1998; Johansson et al., 2001), and promote neuronal survival during times of severe 
cell stress (Fredholm, 1997). Blocking the ongoing influence of A1Rs can precipitate or 
prolong seizures and reduce neuronal survival, and enhancing their actions offers seizure 
protection (Dunwiddie, 1999) and neuroprotection (Fredholm, 1997). Events such as strokes, 
seizures, or other metabolic dysfunctions are associated with a net dephosphorylation of 
ATP and a large increase in extracellular adenosine (Latini & Pedata, 2001) and its inhibitory 
influence via A1Rs can reduce excitotoxicity and short-circuit further metabolic demand. 
Thus adenosine was initially regarded as a “retaliatory metabolite,” as it acts to maintain 
metabolic and network homeostasis during cell stress (Newby, 1984).   
More recently we have recognized that the homeostatic impact of adenosine is regulated 
dynamically under non-pathological conditions, and regulated largely by astrocytes 
(Halassa et al., 2009). ATP and adenosine are released directly from astrocytes (Pascual et 
al., 2005), and ATP is dephosphorylated rapidly to adenosine in the extracellular space 
(Dunwiddie et al., 1997; Cunha et al., 1998); the level of extracellular adenosine is regulated 
primarily by intracellular astrocyte-based adenosine kinase (Gouder et al., 2004; Boison, 
2006).  
3. Purines and autism 
Adenosine affects general arousal, and increased adenosine at A1Rs reduces anxiety; 
conversely, decreased A1R activation can increase anxiety (Florio et al., 1998; Johansson et 
al., 2001). Both A1Rs and A2ARs may be involved in adenosine’s ability to promote sleep 
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(Rainnie et al., 1994; Porkka-Heiskanen, 1999; Huang et al., 2005). Notably, increased seizure 
propensity, disturbed sleep and anxiety are all found commonly in persons with ASD 
(Malow, 2004; Polimeni et al., 2005; Oswald & Sonenklar, 2007), suggesting that an increased 
influence of adenosine could reduce all three co-morbidities.  
In dopamine-containing areas, A2ARs are expressed at higher levels than in other regions, 
and A2ARs have an opposing relationship with dopamine D2 receptors. Increased adenosine 
receptor activation reduces D2 receptor activation (Fuxe et al., 2007), and the two receptors 
form a functional heteromer (Ferre et al., 2007). This complex also seems to be under the 
control of A1Rs, and adenosine agonists have been shown to reduce repetitive behaviors 
(Poleszak & Malec, 2000; Tanimura et al., 2010). Therefore, in addition to reducing general 
excitability through increased A1R activation, adenosine can influence dopamine-related 
behaviors through multiple adenosine receptor subtypes and reduce behavioral pathologies 
- such as repetitive behaviors, which are particularly relevant for ASDs - through these 
interactions. At this time the research evidence linking adenosine to repetitive behaviors is 
growing, but not as strong as the link between adenosine and epilepsy. It is important to 
note that dopamine is involved in many aspects of behavior, and increasing adenosine in 
dopamine-containing areas could impact motivation (Salamone & Correa, 2009); the full 
complement of positive and negative effects and their interactions in ASD would be difficult 
to predict.  
Abnormalities in purine metabolism have been observed in autism (Nyhan et al., 1969; Page 
& Coleman, 2000; Bottini et al., 2001; Marie et al., 2002; Page & Moseley, 2002), but have not 
been linked directly to core symptoms of the disorder or receptor-mediated effects on 
neuronal function, and purinergic strategies have not been exploited for practical clinical 
benefits. Whereas some symptoms and behaviors are likely due to aberrant neuroanatomical 
development and other genetically-determined substrates, increasing the inhibitory 
influence of adenosine could help significantly with multiple behavioral and physiological 
sequelae.  
3.1 Symptoms of autism and regulation of adenosine  
Recent work suggests adenosine dysregulation may be associated with psychiatric disorders 
such as schizophrenia (Boison et al., 2011). In general it is not surprising that a brain-wide 
metabolic/neuronal regulator such as adenosine could influence multiple co-morbidities 
associated with complex psychiatric disorders. The co-existence of neurological/psychiatric 
disorders is also becoming more appreciated, and observed in adults as well as children and 
adolescents (Jones et al., 2008). As just a few examples, there are well-documented 
comorbidities between epilepsy and depression/anxiety (Kanner, 2004, 2008; LaFrance et al., 
2008; Ekinci et al., 2009), schizophrenia (Hyde & Weinberger, 1997), and, more broadly, 
sleep disorders and psychiatric disorders (Reeves et al., 2010), including autism (Spence & 
Schneider, 2009; Jeste, 2011). As noted above, based on behavioral and physiological 
characteristics of ASD, including impaired sleep (Malow, 2004; Polimeni et al., 2005), 
increased seizures (Malow, 2004; Canitano, 2007; Spence & Schneider, 2009), anxiety 
(Chalfant et al., 2007), and perseverative behaviors (Ridley, 1994; Liss et al., 2006), an 
insufficient influence of adenosine might underlie some symptoms. These parallels are 
summarized in Figure 1. Alternatively, even if levels are normal, increased adenosine may 
still be beneficial, offering short term improvements and potentially facilitating more long-
term changes.  
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Fig. 1. Key actions of adenosine in the central nervous system can target multiple symptoms 
of autism. Increased adenosine at the cellular level alters physiology and behavior 
(promoting sleep, and decreasing seizures, anxiety and repetitive behaviors). This cohort of 
outcomes can target overlapping co-morbidities and symptoms of autism (sleep disruption 
and increased seizure propensity, repetitive behaviors and anxiety).  
Research has shown that diverse stimuli such as mechanical pressure or sudden physical 
impact (Franke et al., 2006), seizures (Whitcomb et al., 1990), intense exercise (Dworak et al., 
2007), increased temperature (Masino & Dunwiddie, 1999), decreased pH (Dulla et al., 2005; 
Dulla et al., 2009) and reduced glucose (Kawamura et al., 2010) can all increase brain 
adenosine directly (or indirectly via ATP dephosphorylation: Dunwiddie et al., 1997; Cunha, 
2001; Zhang et al., 2003; Pascual et al., 2005) and thus modulate synaptic transmission within 
minutes. Most of these effects appear to reverse rapidly; others are relatively long-lasting 
(up to hours) or related to chronic changes in physiology. For example, acupuncture has 
been shown to increase local adenosine, perhaps related to the mechanical stimulation 
(Franke et al., 2006; Goldman et al., 2010). Other recent work suggests that a ketogenic diet, 
an effective treatment for pediatric epilepsy, might act via A1Rs (Masino & Geiger, 2008; 
Kawamura et al., 2010; Masino et al., 2011b). Unfortunately, it is impractical to measure 
brain adenosine in humans (necessarily an invasive procedure), and adenosine levels 
outside the central nervous system (e.g., in plasma or urine) are not informative.  
In compiling a list of stimuli known to increase adenosine it becomes apparent that many 
behaviors exhibited by persons with ASDs or shown to improve symptoms could be related 
to one of these physiological changes – e.g. mechanical pressure, including rocking or 
spinning and Grandin’s “hug machine” (Edelson et al., 1999; Escalona et al., 2001), fever 
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(Curran et al., 2007), etc. Therefore, some behaviors expressed by persons with autism could 
be attempts at metabolic and neuronal homeostasis via increased adenosine. Engaging in 
adenosine-increasing activities could thus lead immediately to decreased symptoms of 
autism.  
Ongoing work testing the relationship between adenosine and autism is proceeding in 
animal models. However, because no animal model represents the human condition entirely 
(which itself is a broad spectrum of complex behaviors), we felt it was important to test 
initially for evidence for a link between adenosine and ASD in humans. As noted, direct 
tests in humans to assay or manipulate adenosine in a meaningful way would involve 
highly invasive measurements or manipulations, or, potentially, drugs which are not 
approved in children. Initial work, described below, and coupled with evidence in animals, 
will be building blocks for pursuing this further.  
3.2 Predictions and outcomes - adenosine and autism spectrum disorders 
symptomatology 
Based on animal research suggesting non-pathological stimuli that could increase 
adenosine, we explored the possibility of a beneficial relationship between autism and 
adenosine via a customized behavioral questionnaire focused on behaviors typical of ASD 
(Masino et al., 2011a). Subjects were recruited with the assistance of the Interactive Autism 
Network (IAN) Research Database at the Kennedy Krieger Institute and Johns Hopkins 
Medicine – Baltimore, sponsored by the Autism Speaks Foundation. Participants had 
received a formal autism diagnosis according to DSM-IV criteria made by a qualified 
professional (e.g., psychologist, psychiatrist) and were above a threshold score of 12 on the 
Social Communication Questionnaire (SCQ) parent-report measure (Rutter et al., 2003). 
Autism diagnosis was confirmed by IAN staff; fully 98% of participants ascertained as on 
the spectrum according to standard IAN phenotyping procedures were ASD-positive 
according to clinicians’ best estimate (Lee et al., 2010).  
Along with basic information such as age, diagnosis and verbal level, we queried behavioral 
changes following activities identified as expected to increase, decrease or have no effect on 
adenosine. Our final data set included responses from 155 parents of children with a 
confirmed ASD diagnosis. Parents were naive to all study hypotheses.  
Results from this study revealed a significant relationship between engaging in stimuli pre-
assigned as expected to increase adenosine and parental report of decreased severity of ASD 
symptoms (Masino et al., 2011a). We found a trend for persons diagnosed with Asperger’s 
to show a stronger behavioral effect of adenosine-increasing activities, a finding which 
deserves additional exploration. In general, the significant effects of adenosine-increasing 
activities were unrelated to participant age, gender, or verbal level. These results suggest 
that, if validated, increasing adenosine could have broad applicability to ASD.   
Interestingly, we found a significant relationship between reported caffeine intake and 
reduced symptoms of autism. Because the dose of caffeine was not controlled, and because 
the effect of caffeine on the nervous system is determined by both the dose and the 
frequency, it is not possible to make strong interpretations based on this finding. However, 
akin to the trend for more beneficial effects on persons with Asperger’s, the relationship 
between caffeine and autism deserves further exploration; along these lines, recently others 
have also posited a relationship between caffeine and autism (Ghanizadeh, 2010). Because of 
its well-established safety profile and limited side effects, vast epidemiological database, 
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and known actions in the nervous system, caffeine is being considered as a low-cost 
adjuvant or for its own therapeutic potential in multiple neurological disorders (Arendash & 
Cao, 2010; Cunha & Agostino, 2010; Prediger, 2010; Chen & Chern, 2011).  
4. Metabolic regulation of adenosine - ketogenic diet 
The ketogenic diet is a restrictive diet high in fat and low in carbohydrate that 
significantly reduces the frequency of seizures. Epilepsy is characterized as a disorder of 
unprovoked spontaneous seizures, which affects approximately 1% to 3% of population 
(Shneker & Fountain, 2003); rates of epilepsy in ASD are substantially higher – with 
estimates ranging from 5% up to 40% (Canitano, 2007). The most common treatment for 
epilepsy is antiepileptic drug therapy; the ketogenic diet is a metabolic treatment whereby 
limiting carbohydrates restricts available glucose and initiates ketone-based (ketogenic) 
metabolism. This dietary approach forces the use of ketones for energy, a metabolic shift 
which also occurs during fasting (Aoki, 1981; Hartman & Vining, 2007). Although the 
exact neural mechanisms of the ketogenic diet are currently unknown (although under 
active investigation by a number of laboratories), its efficacy in reduction of seizures has 
been described extensively. In particular, studies have demonstrated that the ketogenic 
diet can decrease seizure frequency by more than 50% in one-third to one-half of children, 
and eliminate seizures in 10-15% of children in 6-12 months (Vining et al., 1998; Keene, 
2006).  
Despite its high success rate, the ketogenic diet is typically offered very infrequently. 
Notable exceptions include proper diagnosis of a very few metabolic conditions where it is 
becoming known as the preferred therapy, and others where it is gaining ground as a 
potential first-line therapy (e.g. GLUT-1 deficiency syndrome). In parallel, it is specifically 
contraindicated for a small set of metabolic conditions (Kossoff et al., 2009). When a 
ketogenic diet is offered, it is typically a “last resort” therapy - after attempting at least two 
(and often more) antiepileptic drugs. The major problems associated with the diet are the 
inconvenience - preparation of special meals – and negative side effects in a subset of 
patients including vomiting, weight loss, increase in serum lipids, acidosis, gastric problems 
or renal stones (Groesbeck et al., 2006; Keene, 2006; Freeman et al., 2007). Although most of 
these are rare or short-term, the diet is usually only prescribed to patients with multiple 
seizures per day, unacceptable drug-related side effects, or seizures that are not sufficiently 
responsive to anti-epileptic drugs.  
Despite a clear link between energy metabolism and brain activity established by historical 
observations and clinical and basic research, the first randomized, prospective, clinically 
controlled study using a ketogenic diet has been published only recently (Neal et al., 2008). At 
last, this much-needed clinical research report proved (at a higher scientific standard – 
prospective, randomized) what had been reported in many other research studies and 
observed clinically for many decades: the ketogenic diet is an effective treatment for pediatric 
epilepsy, and it can be successful even in cases of medically-intractable epilepsy (Kinsman et 
al., 1992; Vining et al., 1998). In this study, the number of seizures observed in children placed 
on the diet decreased by 38% in three months. In contrast, the number of seizures observed in 
a matched group of children who continued their current treatment increased by 37% in 3 
months. In some children who started the ketogenic diet seizures stopped entirely, whereas 
this was never observed in the control group. This report and an accompanying commentary 
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(Wiznitzer, 2008) note that the critical mechanisms underlying the success of the diet remain 
unknown, and this knowledge gap has thus far stymied efforts to develop treatments based on 
the metabolic changes precipitated by the ketogenic diet.  
Recent research suggests that the ketogenic diet may act by increasing the influence of 
adenosine acting at A1Rs (Masino & Geiger, 2008; Kawamura et al., 2010; Masino et al., 2011b). 
Other research suggests that the ketogenic diet acts by reducing reactive oxygen species and 
oxidative stress (Sullivan et al., 2004; Davis et al., 2008), direct actions of ketone bodies on ion 
channels (Ma et al., 2007) or transporters (Juge et al., 2010), or increased GABA (Yudkoff et al., 
2007). Any of these mechanisms could be highly beneficial in ASD, which is associated with 
disinhibition (Hussman, 2001; Fatemi et al., 2009a,b) and oxidative stress (James et al., 2004; 
McGinnis, 2005; James et al., 2006). While the link between the efficacy of the ketogenic diet 
and increased adenosine is still emerging, there are at least 3 strong reasons why – based on 
well-established evidence - a ketogenic diet could be helpful in autism:  
1. The ketogenic diet treats epilepsy. A high percentage of children with autism have 
epilepsy. Importantly, these numbers might be higher with the routine ability to 
measure electrographic (non-behavioral) seizures and altered subcortical activity.  
2. The ketogenic diet reduces reactive oxygen species and oxidative stress. Autism is 
associated with increased oxidative stress.  
3. Most importantly, an established, medically-supervised diet-based strategy is cost-
effective and available to translate immediately into practical benefits.  
It is important to note that both adenosine and a ketogenic diet can stop drug-resistant 
epilepsy, suggesting mechanisms other than those targeted by existing drugs. Both mobilize 
a broad homeostatic bioenergetic regulation (Boison et al., 2011) and thus may be best suited 
to address a broad spectrum of symptoms with limited side effects.  
Since we published a hypothesis that a key therapeutic aspect of a ketogenic diet is to 
increase adenosine acting via A1Rs (Masino & Geiger, 2008) this hypothesis has been tested 
in three ways: (1) we explored an in vitro model of ketogenic diet electrophysiologically in 
individual neurons, (2) we administered a ketogenic diet in vivo to three types of transgenic 
mice, all with spontaneous electrographic seizures due to decreased A1R signaling, and (3) 
we tested the ability of a ketogenic diet to reduce pain and inflammation, a prediction of this 
hypothesis. Respectively, we found that (1) metabolic conditions designed to mimic a 
ketogenic diet in brain slices mobilized a novel autocrine regulation of neuronal activity via 
adenosine acting at A1Rs (Kawamura et al., 2010), (2) a ketogenic diet reduced 
electrographic seizures in mice with intact A1Rs, but did not in mice lacking A1Rs (Masino et 
al., 2011b), and (3) a ketogenic diet reduced pain and inflammation, as predicted (Ruskin et 
al., 2009).  
While data continue to emerge, and multiple mechanisms could play a role, together these 
studies suggest that a ketogenic diet reduces seizures by increasing adenosine-mediated 
inhibition and offer insight into therapies for other clinical conditions where adenosine is 
known or hypothesized to offer clinical benefits. Using a retrospective analysis, we explored 
the effects of the ketogenic diet on behavior and temperament of children with epilepsy with 
or without hallmark symptoms of autism.  
4.1 Ketogenic diet - retrospective analysis in children 
To evaluate the effects of a ketogenic diet on symptoms of autism, alongside changes in 
seizure frequency, behavior and mood, we identified children who began dietary therapy 
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because of their epilepsy diagnosis. Based on decades of research and consistent clinical 
findings, we expected diet therapy to reduce seizures significantly in the majority of these 
children. At the same time, because of the high incidence of epilepsy in children with autism, a 
subset of these children with pediatric epilepsy exhibited co-morbid symptoms of ASD. Thus, 
we were able to assess changes in behavior in children with or without symptoms of ASD in 
parallel with other physiological and neurological outcomes of diet therapy. In this way we 
examined the outcomes based on treatment with a standard diet protocol, available currently 
to any clinician and in use at many centers nationally and globally.  
Using a retrospective analysis we examined clinical and behavioral features of children with 
epilepsy between 18-months and 12-years of age who initiated the ketogenic diet at 
Connecticut Children’s Medical Center between January 2004 and January 2009. All aspects 
of the study were approved by the Institutional Review Board. Potential participants in this 
retrospective study were identified using the ketogenic diet database at the Connecticut 
Children’s Medical Center. Because some measures used in this study are only available 
currently in English, children with non-English speaking parents were excluded.  
Parents of selected children were invited to participate in the study with a phone call. After 
obtaining a verbal consent, questionnaires were mailed to the parents. The participating 
children, whose parents filled out the questionnaires, were divided into two groups: subjects 
currently on the ketogenic diet (KD group) and subjects who discontinued the ketogenic 
diet (non-KD group). Children in the KD group had stayed on the diet for at least 6 months, 
and children in the non-KD group stopped the diet at least 2 months before the testing. 
Demographic and clinical data were collected from chart review.  
Statistical analyses (Student t-test, Pearson test, and chi-square test) were performed to 
compare the differences between the KD group and the non-KD group. To dissociate 
differences related to either autism or cognitive impairment, subjects who were assessed as 
autistic based on their Child Autism Rating Scale score (filled out by parent) and subjects 
who were evaluated as cognitively impaired by a neurologist were analyzed separately.  
In this initial retrospective analysis there was no difference in the number of boys versus 
girls (10 each) and no substantial difference in the number of children who were still on the 
ketogenic diet versus those who continued the diet (11 and 9, respectively) or the average 
age of the KD versus non-KD group (6.4±0.8 and 8.3±1.1, respectively, P=0.18). We expected 
to find a significant different in seizure frequency, and although there was a trend in the 
average number of seizures per week in each group (KD group, 16±8 seizures per week; 
non-KD group, 99±52 seizures per week) there was high variability (and thus the lack of 
significance) due primarily to two clinically-expected outcomes: (1) some children in the 
non-KD group became seizure-free after being on the diet, and went off the diet with a 
current score of zero seizures per week; (2) children who did not comply and stay on the 
diet, or for whom the diet didn’t work, had more than 100 seizures per week. Both of these 
types of cases were included in the non-KD group. These data are summarized in Table 1.  
 
 KD Group Non-KD group P value 
Number 11 (6 females) 9 (4 females) 1.0 
Age 6.4±0.8 8.3±1.1 0.18 
Number of Seizures/week 16±8 99±52 0.10 
Table 1. Summary statistics of children who were on the ketogenic diet (KD-group) or children 
who started but were not currently on the ketogenic diet (non-KD group) at Connecticut 
Children’s Medical Center from January 2004-January 2009. See text for additional details.  
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We also considered whether the children were autistic only, cognitively impaired only, or 
autistic and cognitively impaired. There was no difference in the number of children who 
were autistic and cognitively impaired in each group (KD group:  5/11; non-KD group: 
4/9); the numbers in other categories were too small for statistical comparison.  
Statistical analysis of data from the Child Behavior Checklist showed that subjects who were 
still on the ketogenic diet (KD group, n=11) had significantly fewer behavioral problems 
than subjects who were no longer on the ketogenic diet at the time of testing (non-KD 
group, n=9; 2 (1), P<0.05). When analyzing separately cognitively impaired children and 
autistic-like children, we found that in both of these subgroups, the subjects who were 
currently on the ketogenic diet (KD group) had better behavioral traits than subjects who 
had already stopped ketogenic diet treatment (non-KD group); P<0.001 and P<0.01, 
respectively; (Svedova et al., 2010). Effects of the ketogenic diet on behavior of children will 
continue in ongoing retrospective and prospective studies.  
Although these data are preliminary, they add to positive outcomes discussed below in 
previous prospective studies (Pulsifer et al., 2001; Evangeliou et al., 2003) and anecdotal 
reports. Along with evidence that a ketogenic diet increases A1R activation, evidence that 
A1Rs decrease anxiety, and evidence that either a ketogenic diet or A1R activation decreases 
seizures, a proven metabolic approach such as a ketogenic diet should be considered for 
ASDs.  
4.2 Ketogenic diet, adenosine and autism 
Previous studies have shown that autism is caused by one or more gene defects, which can 
affect brain development, cell signaling, cell transport or structure (Santangelo & Tsatsanis, 
2005; Zhao et al., 2007). It has been suggested that some of these gene defects may result in 
metabolic dysfunctions that can eventually cause behavioral abnormalities associated with 
autism, and several metabolic disorders present symptoms similar to autism, underscoring a 
link between autism and metabolism (Zecavati & Spence, 2009).  
Based on these findings, there have been numerous attempts to treat autism with different 
types of restrictive diets, and dietary therapies remain popular in the autism community. 
Here we have focused our discussion primarily on the ketogenic diet, based on (1) the 
proven clinical success of the ketogenic diet for epilepsy, and preliminary positive results 
with autism, (2) in vivo and in vitro research evidence linking the ketogenic diet to 
adenosine, and (3) a recent retrospective study of the classic ketogenic diet in children with 
epilepsy and autism, discussed above.  
In general, gastrointestinal problems and metabolic disturbances appear to be closely 
related to ASD, and there are several known metabolic impairments that are associated 
with autistic symptoms. These include phenylketonuria, adenylsuccinate lyase deficiency, 
histidinemia, or hyperuricosuric autism (Page & Coleman, 2000). The prevalence of food 
allergies (Gurney et al., 2006) and the incidence of at least 25-30% of children with autism 
suffering from chronic diarrhea, constipation or food issues (Page & Coleman, 2000; 
Ibrahim et al., 2009), suggest that some types of ASD may be treated with dietary 
restrictions. In the past few decades, several diets have been described in terms of their 
effects on symptoms of autism, including gluten-free, casein-free (GFCF) diet, specific 
carbohydrate diet, body ecology diet, or ketogenic diet (Srinivasan, 2009). A survey by 
Witwer and Lecavalier (2005) estimated that 15.5% of autistic children or adolescents were 
on modified diets for treatment of autism. It should be noted that that in several studies, 
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including a double-blind placebo-controlled intervention, the GFCF diet was found to 
have no benefits for ASD (Elder et al., 2006; Millward et al., 2008), and has been associated 
with protein malnutrition (Arnold et al., 2003). Thus, the specificity of GFCF approaches 
to symptoms of ASD should be viewed with caution.  
Direct evidence supporting a beneficial relationship between a ketogenic diet and autism 
comes from one published report – a prospective study - which tested the effects of a 
ketogenic diet in children with autism (Evangeliou et al., 2003). However, there are multiple 
unpublished anecdotal reports (Beth Zupec-Kania, personal communication), including 
reports of dramatic success with a ketogenic diet in autism. In the prospective study, 
Evangeliou et al. applied a ketogenic diet protocol to children with autism and found that 
60% of diet-compliant children aged 4-10 who participated for 6 months showed an 
improvement in their symptoms. Significant improvement (> 12 points on the Childhood 
Autism Rating Scale) was recorded in 2/18 patients, average improvement (> 8-12 points) in 
8/18 and minor improvement (> 2-8 points) recorded in 8/18. Notably, the diet protocol 
included 4 weeks on and 2 weeks off the ketogenic diet - a different regimen than 
administered typically for treatment of epilepsy. Still, these results are promising and 
provide preliminary data supporting a link between a ketogenic diet and autism, and 
potentially among autism, adenosine and a ketogenic diet. The biggest improvements were 
quantified in those patients who showed only mild autistic behavior, similar to our findings 
for a trend for the biggest benefit for adenosine–increasing activities in individuals with 
Asperger’s (Masino et al., 2011a).  
In addition to a reduction of their seizures, children on the ketogenic diet can enjoy other 
benefits - including reduced drug intake and general improvements in cognition, alertness, 
development, attention and social life (Kinsman et al., 1992; Sirven et al., 1999; Pulsifer et al., 
2001; Hallböök et al., 2007; Hallböök et al., 2007), and - as we found in our retrospective 
study - fewer behavioral problems (Svedova et al., 2010). However, the number of studies 
researching the effects of the ketogenic diet on behavior and cognition of children remains 
surprisingly limited. A single prospective study conducted by Pulsifer et al. (2001) focused 
on the effects of the ketogenic diet on behavior and development of children with intractable 
epilepsy. The children were evaluated at the diet initiation and after one year using three 
parental report measures: Developmental Profile-2nd edition, Child Behavior Checklist, and 
Parenting Stress Index-Short Form. The results demonstrated an overall significant 
improvement in developmental functioning. In addition, the Child Behavior Checklist 
showed a significant improvement in attention and social problems. Interestingly, the 
authors commented that the developmental and behavioral improvements were not 
statistically related to better seizure control or to reduced intake of antiepileptic drugs.  
A recent study examining the efficacy of writing parental goal letters prior to initiating the 
ketogenic diet showed that improvements in cognition and alertness were stated as the third 
most common goal (Farasat et al., 2006). Interestingly, the study suggested that cognition 
and alertness improvements were more likely to lead to long-term adherence to the diet – 
more so than improved seizure control or a decreased intake of antiepileptic drugs. From 
this observation, it is evident that potential improvements in cognition and behavior are 
crucial for many parents. Unfortunately, as noted above, and despite many decades of 
clinical use, there is a limited literature exploring the effects of the ketogenic diet on 
behavior and cognition of children. However, a wealth of resources about the ketogenic diet 
can be found on-line at the Charlie Foundation (www.charliefoundation.org).  
 
Adenosine and Autism - Recent Research and a New Perspective 
 
113 
5. Conclusions 
Here we propose adenosine as a beneficial neuromodulator for ASD symptoms based on 
published research, behavioral and physiological symptoms of autism, and recent indirect 
evidence obtained in children (parent report via a customized adenosine questionnaire and 
retrospective analysis of children with epilepsy and with or without hallmark symptoms of 
autism). Obtaining direct evidence (measuring adenosine accurately in humans) is too 
invasive, and drugs that may increase adenosine have not been specifically established as 
such, would need to be used “off-label,” and are not approved for use in children. Gathering 
correlated evidence regarding changes in adenosine in animal models can proceed in parallel 
with the type of “proof-of-principle” work gathered in humans and presented herein.  
Beyond clinical endpoints indicating that increased adenosine would be beneficial in autism 
– e.g., reduced seizures - adenosine would be predicted to be increased by the atypical 
behaviors sought by persons with autism and offer short term benefits. Similarly, a 
ketogenic diet would be predicted to reduce symptoms of autism. Our customized 
questionnaire demonstrated highly significant changes - ASD symptoms were reduced after 
stimuli predicted to increase adenosine. These initial results should be followed up with 
more detailed controlled and prospective studies, and include stimuli that have been 
verified to increase adenosine. In this respect, two conditions that might increase adenosine 
(in different ways) include acupuncture and a ketogenic diet. Published research 
(Evangeliou et al., 2003) and our retrospective study, described in more detail here, suggest 
that a ketogenic diet does indeed offer multiple benefits for children with ASD.  
Ketogenic diet is an existing treatment option at many institutions treating pediatric 
epilepsy, and diet therapy appears to be increasing in popularity. Diet therapy works 
typically within two weeks and certainly within three months, and thus clinical efficacy is 
determined relatively rapidly after starting treatment. Even though the ketogenic diet is 
now established as a clinically effective treatment in pediatric epilepsy, it has not been 
explored adequately in other developmental disorders - such as autism - that may benefit 
from seizure control and relief from diverse co-morbid symptoms. A more comprehensive 
overview of the diverse potential benefits of a relationship between a ketogenic diet and 
adenosine, including autism, is outlined in Masino et al. (2009).  
It is important to remember that ketogenic diet therapy can result in a permanent reduction 
in epileptic seizures, and some children remain seizure-free even after tapering off the diet. 
The implication that permanent benefits could be achieved in ASD is incredibly enticing - 
although there is no evidence at this time. Notably, however, the ketogenic diet is often 
effective in treating seizures which are medically-refractory. In parallel with ongoing use of 
the classic ketogenic diet, related dietary strategies such as low glycemic index therapy 
(LGIT; Pfeifer & Thiele, 2005; Muzykewicz et al., 2009) and the modified Atkins diet (MAD; 
Kossoff et al., 2003; Kossoff et al., 2008) are actively investigated for efficacy in epilepsy. 
Because these diets are less restrictive than the standard ketogenic diet, they offer more 
popular appeal and may represent different “doses” of a ketogenic diet. The classical 
ketogenic diet is the most strict – highest “dose” and in some cases can offer seizure control 
in patients who did not achieve sufficient control with the MAD (Kossoff et al., 2010).  
Because there is neither a proprietary drug nor drug development required, clinically-
proven dietary strategies are translatable immediately to another pediatric population such 
as autism. Although used less often, the ketogenic diet is effective in adults with epilepsy, 
and thus could be considered for adults with ASD. There are currently no established 
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effective treatments for ASD in children or adults, and no approved psychiatric drugs for 
children, making the risks relatively small and the potential benefits quite large. A drug-
based strategy would be easier to administer and appeal to a wider patient population; a 
“ketogenic diet in a pill” remains a hotly pursued therapeutic target (Rho & Sankar, 2008).  
In general, a metabolic approach to increase adenosine could offer positive reinforcement, 
including improved sleep and learning, and reduced seizures and anxiety. The combined 
evidence of abnormal purine metabolism, stereotyped behaviors, increased seizures and 
disrupted sleep suggests a general dysregulation of this modulator and thus potential new 
insight into therapies for ASD. Success with metabolic adenosine-increasing approaches 
could also provide an impetus for exploring adenosine-enhancing drugs in autism, and 
establishing their safety and efficacy in children.  
This work linking adenosine and autism integrates behavioral and neurobiological data, 
puts forth a new theory regarding ongoing symptoms of autism, and - if translated to 
clinical benefits - could address several areas of critical need. First, it targets co-morbidities 
in the form of anxiety, sleep, and seizure disorders. It is well known that sufficient quality 
and quantity of sleep is crucial for general mental health and optimizing learning and 
memory. Second, it proposes a specific and novel neurobiological target for reducing the 
ongoing symptoms of autism spectrum disorder – increased extracellular adenosine. Third, 
it targets metabolic mechanisms that alter adenosine, rather than receptor-based strategies. 
For decades researchers have attempted to develop adenosine-receptor based therapeutics 
but side effects, particularly due to peripheral actions of adenosine, remain a roadblock 
(Dunwiddie, 1999; Boison et al., 2011). This physiologic/metabolic approach, which shifts 
the dynamic level of adenosine itself, is likely to have far fewer side effects when translated 
into humans. Thus, some stimuli for increasing adenosine levels and decreasing ASD 
symptoms may be immediately accessible environmental interventions involving changes in 
diet or behavior, in parallel with pursuing more traditional pharmaceutical interventions.  
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